Full results from the global SAFFRON phase III trial, presented at ESMO 2026 and published in The New England Journal of Medicine, show savolitinib plus osimertinib delivered statistically significant improvements in both progression-free and overall survival over chemotherapy in MET-driven, EGFR-mutated lung cancer. A US marketing application has already been filed.

What was announced

HUTCHMED (China) Limited (LSE:HCM) said on 26 October 2026 that detailed SAFFRON data were presented in Presidential Symposium II at the ESMO Congress 2026 in Madrid, as abstract LBA6, on 25 October. The results were simultaneously published in The New England Journal of Medicine.

SAFFRON is a randomised, open-label, multi-centre, global phase III trial. It enrolled 338 patients at 230 centres in 29 countries with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) showing MET overexpression or amplification, whose disease had progressed after first- or second-line treatment with TAGRISSO (osimertinib). Patients received ORPATHYS (savolitinib) 300 mg twice daily plus TAGRISSO 80 mg once daily, or doublet platinum-based chemotherapy. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED (LSE:HCM) and commercialised by AstraZeneca.

The numbers

The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Median PFS was 7.6 months (95% CI 5.6–9.7) for the combination compared with 5.4 months (95% CI 4.2–5.8) for chemotherapy, with a hazard ratio of 0.55 (95% CI 0.42–0.72; p<0.001). The company describes the result as statistically significant; on the disclosed figures, the hazard ratio corresponds to a 45% reduction in the risk of progression or death. The 12-month PFS rate was 36% versus 10%.

Overall survival (OS), the key secondary endpoint, also showed a statistically significant improvement. Median OS was 17.8 months (95% CI 15.6–23.7) versus 12.9 months (95% CI 10.6–16.8), a difference of 4.9 months, with a hazard ratio of 0.68 (95% CI 0.50–0.91; p=0.010). The 12-month OS rate was 70% versus 53%.

In the MET-overexpressed analysis set, median PFS was 8.5 months versus 5.6 months, with a hazard ratio of 0.51 (p<0.001). In the MET-amplified set, median PFS was 7.64 months versus 4.2 months, with a hazard ratio of 0.487, although no formal statistical testing was carried out for that group. The data cut-off was 6 July 2026.

Grade 3 or higher treatment-emergent adverse events occurred in 64% of patients on the combination and 63% on chemotherapy, while median treatment exposure was 8.5 months versus 3.5 months. HUTCHMED said there were no new safety concerns.

What the company and partners said

Professor Shun Lu of Shanghai Chest Hospital, the global lead principal investigator, said: "These results have the potential to establish a new global standard of care."

Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: "Precision inhibition with ORPATHYS alongside TAGRISSO offers a meaningful, all-oral option." Dr Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, described the combination as potentially "the first biomarker-directed, all-oral treatment option in this setting."

Regulatory position and what to watch next

A New Drug Application has been submitted to the US Food and Drug Administration for patients with high MET overexpression or amplification, and HUTCHMED said submissions in Europe and Japan are progressing as planned. The combination is already approved in China, based on the SACHI phase III trial.

The release does not give a timetable for an FDA decision. Investors will watch for confirmation of FDA acceptance and review timelines, the progress of European and Japanese filings, and how AstraZeneca positions the combination commercially. HUTCHMED also highlighted SANOVO, a separate phase III trial of the combination in previously untreated patients in China, which was due to be presented at ESMO as abstract LBA69 on 26 October.